Thirumalai Chemicals Limited Overview
Thirumalai Chemicals is a five-decade-old Indian producer of phthalic anhydride (PAN) and its derivatives, and of maleic-anhydride-based food acids (malic and fumaric acid). It is India's second-largest PAN producer behind I G Petrochemicals, describes itself as among the world's top three PAN manufacturers, the largest fumaric-acid producer in India, and the largest maleic anhydride (MAN) producer in Southeast Asia through its Malaysian subsidiary. Historically a cash-generative, near-debt-free commodity chemicals franchise (FY2022 consolidated PAT of INR 281 Cr), TCL has since FY2023 undertaken a transformational, largely debt-funded investment cycle: a large PAN/fumaric expansion at Dahej, Gujarat, and a greenfield MAN and food-acids complex in New Martinsville, West Virginia, now budgeted at USD 340 million. The combination of compressed PAN–orthoxylene spreads, idle Malaysian capacity and US project cost overruns has produced three consecutive loss-making years, a sharply higher leverage profile, covenant waivers and five ICRA downgrades since May 2025. The equity story is now a binary bet on US commissioning (targeted December 2026) and balance-sheet repair.
What the company does
Thirumalai Chemicals manufactures and sells organic chemicals in two broadly related value chains:
-
Phthalic anhydride chain (bulk/commodity): PAN is produced by catalytic oxidation of ortho-xylene (OX) at Ranipet (Tamil Nadu) and at Dahej (Gujarat, via subsidiary TCL Intermediates Pvt Ltd). PAN is sold to plasticiser makers (PVC cables, flooring, films), unsaturated polyester resin (UPR) producers (fibre-reinforced plastics), alkyd-resin/paint manufacturers, and copper phthalocyanine (CPC) pigment makers. Downstream PAN derivatives include diethyl phthalate (DEP), phthalate esters and phthalimide (PID).
-
Maleic anhydride and food-acid chain (specialty): MAN is produced from butane (Malaysia; US under commissioning). MAN is the feedstock for malic acid and fumaric acid, which TCL sells in food, beverage, confectionery, bakery, animal feed, pharmaceutical (fumaric acid as API), personal-care and industrial (UPR, alkyd resin, inks) applications. TCL produces both food-grade and pharma-grade malic acid at Ranipet.
Per the FY26 Annual Report, revenue mix is approximately 84% bulk commodity and 16% specialty chemicals.
A secondary capability is TCL Technology & Engineering (TCL-TE), an in-house division that designs, fabricates and supplies "ready-to-start-up" modular process plants and skids. TCL-TE built the modules for the West Virginia project. TCL also historically generated wind power in Tamil Nadu; four windmills are being sold (Aug 2026).
Company's own description (paraphrased from FY2025-26 Annual Report)
The company presents itself as a globally integrated specialty chemicals group that evolved from a single PAN plant at Ranipet into a multi-product, multi-geography enterprise operating in India, Malaysia and the United States, with more than 350 customers across roughly 60 countries. It emphasises that its products go into everyday goods — paints, cable plasticisers, beverage acidulants and pharmaceutical ingredients — and that a key differentiator is the ability to span both industrial-grade and food-grade production within an integrated manufacturing model. Management highlights energy self-sufficiency (over 90% of PAN-operations energy from recovered process heat), zero liquid discharge at Ranipet, and a long-term, discipline-first culture rather than aggressive diversification.
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | ~100% product sales (manufactured chemicals). No subscription or licensing revenue disclosed. Engineering (TCL-TE) is primarily captive. Wind-power income historically immaterial (power segment de-recognised as reportable in 2018) |
| Pricing | Spot and contract pricing; ICRA notes medium- to long-term contracts with many customers, but realisations track regional PAN supply–demand and OX costs |
| Key input | Ortho-xylene, sourced under a long-standing relationship with Reliance Industries on an "assured offtake model" (ICRA); butane for MAN (Malaysia, US); MAN for food acids; ethanol for DEP |
| Value-chain position | Mid-stream intermediate producer: buys petrochemical feedstock, sells intermediates to formulators/converters. Limited product differentiation in PAN; more differentiation (food/pharma grades, certifications) in food acids |
| Customer types | Plasticiser and resin manufacturers, paint and pigment makers, food and beverage processors, pharmaceutical companies, animal-feed producers, personal-care/fragrance formulators (DEP) |
| End-markets | Construction/infrastructure, automotive, paints and coatings, food and beverage, pharmaceuticals, personal care (ICRA, Jun 2026) |
| Geographic sales | FY26: ~90% India, ~10% exports (Annual Report); export mix Europe 43%, North America 25%, Asia 19%, Africa 13% |
Independent characterisation
TCL is best understood as a spread business with an embedded growth option. The core Indian PAN franchise earns the PAN–OX spread, which is set largely by Chinese and Korean supply and by anti-dumping protection in India; when spreads are healthy (FY2022) the business generates 20%+ EBITDA margins and strong free cash flow, and when spreads compress (FY2024–FY2026) margins collapse to low single digits or negative. The food-acids business is structurally more attractive — higher value, sticky regulated customers — but it is small relative to PAN and its MAN feedstock economics have been undermined by Chinese oversupply, which has rendered the Malaysian MAN plant largely non-operational. The West Virginia project is a strategic attempt to relocate the higher-value MAN/food-acids chain into a tariff-protected, under-supplied North American market with advantaged shale-gas butane. The problem is that it has been financed predominantly with debt at the same time the core PAN cash engine stalled, producing a classic capex-cycle squeeze.
Strategy
Stated strategy (FY2025-26 Annual Report themes, paraphrased)
The FY26 report is themed around "Growing from Strength to Strength", built on three pillars — Expansion (measured growth across India, Malaysia and the US, staying close to served markets), Innovation/process discipline (continuous improvement of processes, efficiency and quality), and Transformation (becoming more agile, integrated and aligned with a changing global environment). The Chairman's stated near-term priorities are to improve EBITDA through higher volumes and better realisations, keep tight control of working capital, and use operating cash flow to reduce debt and finance costs. He explicitly frames strategy as concentrating on areas of deep technical expertise rather than aggressive diversification, and expects improved operating leverage, stronger cash generation and gradual deleveraging as Dahej reaches full contribution and the US project progresses.
Strategic initiatives (last 24 months)
| Initiative | Description | Status / targets | Source |
|---|---|---|---|
| West Virginia MAN & food-ingredients complex | 40,500 TPA MAN from local butane; 30,000+ TPA malic/fumaric acid; proprietary low-capex technology; modular build by TCL-TE; positioned to replace imports in an under-served US market and export to LATAM/Europe | First MAN unit started Jan 2026; full commissioning slipped to Dec 2026; cost revised from USD 255 m to USD 340 m (incl. working capital and cash buffer); food-ingredient ramp requires customer approvals | ICRA Aug 2026; company filings |
| Dahej Phase II stabilisation | ~96,000 TPA PAN and ~10,000 TPA fumaric acid commissioned FY2025 | Fully stabilised; ~95% utilisation in Q1 FY27 | FY26 AR; Q1 FY27 presentation |
| Balance-sheet repair programme | Preferential issues (~INR 507 Cr in FY26); board approval for up to INR 750 Cr via debt/equity incl. possible QIP; reported plan for INR 200–250 Cr preferential issue; refinancing; US senior secured term loan up to USD 130 m (reports cite USD 130–180 m facility) | Ongoing; Fund Raising Committee met 30 Aug 2026 | Filings; news |
| Non-core asset monetisation | Sale of four windmills (INR 10.35 Cr) to TN Oxygen; OOSB divestment via Cheminvest (reported INR 100–150 Cr); possible sale of Ultramarine & Pigments stake | Windmills approved; others pending/unconfirmed | Filings; CNBC-TV18 via secondary |
| Trade protection | Successful sunset review: anti-dumping duty on PAN from China and Korea continued for five years from Aug 2026 | Effective | Customs Notification 20/2026 |
| Operational excellence | Re-catalysation of Ranipet PAN; procurement transformation (Best Procurement Transformation Award 2025); inventory reduction; real-time quality monitoring | Ongoing | FY26 AR; Q1 FY27 presentation |
| ESG 2030 targets | -25% GHG, -10% water consumption, -10% industrial waste vs. FY2022-23 baseline; zero accidents; 100% digitally enabled workforce | FY26 progress reported (see Section 20) | FY26 AR |
| Leadership build-out | CEO role (Sanjay Sinha); President-Finance (Feb 2026); US subsidiary CEO (Dec 2025); auditor rotation to PKF Sridhar & Santhanam | Completed | Filings |
Medium-term guidance
TCL does not publish quantitative revenue/margin guidance. The only forward-looking quantitative commitments identified are the US project budget (USD 340 m) and timeline (full commissioning Dec 2026), the 2030 ESG targets, and the fund-raising envelope (up to INR 750 Cr). Management's AGM-notice language anticipates improved productivity and profitability as projects reach optimal utilisation, without numbers.
Products & Services
PAN chain (bulk commodity, ~84% of revenue)
| Product | Description & specifications | Manufacturing site / capacity | Target customers / applications | Status / year | Pricing |
|---|---|---|---|---|---|
| Phthalic Anhydride (PAN/PA) | Produced by catalytic oxidation of ortho-xylene; flake/molten forms. Company claims top-3 global producer status | Ranipet (TN) and Dahej (GJ). Total PAN capacity ~1,72,000 TPA incl. Dahej phase I per ICRA, with Dahej phase II adding ~96,000 TPA in FY2025 (ICRA text is ambiguous whether 172k includes phase II) | Plasticisers (PVC), unsaturated polyester resins, alkyd resins/paints, CPC pigments, dyes, herbicides, fire retardants, polyester polyols, rubber scorch inhibitors | Flagship since 1973/76; Dahej phase II FY2025; Dahej at ~95% utilisation in Q1 FY27 | Spot/contract; tracks PAN–OX spread; protected by Indian anti-dumping duty (USD 40.08/MT China, USD 140.17/MT Korea, from Aug 2026) |
| Diethyl Phthalate (DEP) | Phthalate ester from ethanol + PAN; high solvency/purity | Ranipet | Fragrance and cosmetics solvent; plasticiser for medical/packaging plastics; adhesives, insect repellents | Established | — |
| Phthalate esters (other) | PAN downstream derivatives | Ranipet/Dahej (not specified) | Plasticisers | Established; contribution growing (ICRA) | — |
| Phthalimide (PID) | PAN derivative | Not specified | Agro/pharma intermediates | Listed in ICRA company profile | — |
MAN and food-acids chain (specialty, ~16% of revenue)
| Product | Description & specifications | Manufacturing site / capacity | Target customers / applications | Status / year | Pricing |
|---|---|---|---|---|---|
| Maleic Anhydride (MAN) | Butane-based oxidation route | OOSB Kemaman, Malaysia: 50,000 TPA (largely idle FY26, positive EBITDA Q1 FY27). TCL Specialties, West Virginia: ~40,500 TPA (first phase start-up Jan 2026; full commissioning targeted Dec 2026) | UPR/composites, lubricant additives, agrochemicals, feedstock for malic/fumaric acid; US North-East and Mid-West customers (under-served regionally) | Malaysia: long-established; US: 2026 | Not disclosed; MAN realisations pressured by Chinese supply (ICRA) |
| Malic Acid | Acidulant; food-grade and pharma-grade (company cites itself as among few Indian producers of both) | Ranipet; US food-ingredients plant (30,000+ TPA combined malic + fumaric) | Beverages, confectionery, food processing, oral care/skincare, metal cleaning, textile dyeing, paint anti-skinning | India: since 1992; US: ramp-up from Dec 2026 (customer approvals required) | — |
| Fumaric Acid | Acidulant, leavening agent; API grade | Ranipet; Dahej phase II (~10,000 TPA); US plant | Bakery, tortillas, animal feed, bath salts, UPR and alkyd resins, inks, pharmaceutical API | Company claims largest Indian producer | — |
| Food ingredients (historic) | Tartaric acid and salts, maleic acid cited in older company descriptions | Not specified | Food | Current production not confirmed in FY26 AR | — |
Services and other
| Offering | Description | Status |
|---|---|---|
| TCL Technology & Engineering (TCL-TE) | Design, supply and construction of modular, IoT-enabled process plants and skids; built US plant modules in India (plus fabrication in Japan and the US) | Captive; external revenue not disclosed |
| Proprietary process technology | "Hi-efficiency, low investment" MAN/food-acid technology licensed intra-group to TCL USA; described by the company as patented | Captive |
| Wind power (Tamil Nadu) | Four windmills | Board approved sale to TN Oxygen Pvt Ltd for INR 10.35 Cr (Aug 2026) |
Financial Narrative
Income statement
Sources and notes: Revenue, gross profit, EBIT, finance costs — S&P Global Market Intelligence (StockAnalysis, data updated Aug 2026). EBITDA, PBT, PAT — FY26 Annual Report five-year performance snapshot and FY26 results filing (PBT FY26 per filing INR -201.8 Cr; AR snapshot INR -194 Cr). EPS derived as PAT ÷ weighted shares (FY22–FY25: 102.39 m shares; FY26 weighted ≈112.6 m after Aug and Dec 2025 allotments); no dilutive instruments identified, so diluted = basic. DPS derived from cash dividends paid in the following year (INR 25.6 Cr, 15.4 Cr, 10.2 Cr) and Screener payout ratios; no dividend for FY25 or FY26. ICRA computes FY26 OPBDIT/OI at -1.4% (≈INR -24 Cr) versus company EBITDA of INR -16 Cr — definitional difference.
Margins and growth
Revenue CAGR: FY2022–FY2026 (4-year) -3.5%; FY2021–FY2026 (5-year, FY21 base ≈INR 1,086 Cr derived from S&P growth rate) ≈+9.8%, consistent with Screener's ~10% five-year standalone sales CAGR.
Commentary. FY2022 was a super-cycle year: post-COVID restocking, tight Asian PAN supply and a strong MAN market lifted revenue 84% and EBITDA margin to ~23%. From FY2023 the PAN–OX spread compressed as Chinese and Korean capacity returned and new large Indian capacities came on stream (ICRA), cutting gross margin by almost half by FY2024. FY2024–FY2025 revenue was broadly flat because Dahej volumes offset lower realisations, but EBITDA stayed near INR 70 Cr. FY2026 is the inflection low: revenue fell 15% on weaker volumes and pricing (Middle East conflict, tariff disruption, subdued global demand per the Chairman's letter), operating efficiencies fell with lower utilisation, finance costs nearly doubled to INR 80.6 Cr as capex debt matured into the P&L, and OOSB's MAN plant was largely idle. The negative tax line (S&P: INR -24.9 Cr TTM credit) cushioned PAT only marginally.
Quarterly trajectory (consolidated)
Sources: Quarterly results filings via Kotak Securities, MarketsMojo, Univest; Q4 FY26 PAT derived as FY26 PAT minus 9M (aggregator reports of INR -10.83 Cr / -27.42 Cr appear to be standalone figures). Q1 FY27: EBITDA INR 35.9 Cr (6.6% margin) vs. INR -24.5 Cr in Q1 FY26; interest expense INR 51.97 Cr (9.5% of revenue); standalone PAT turned positive at INR 14.21 Cr vs. INR -13.83 Cr a year earlier. Q1 FY27 revenue was the highest quarterly print in over two years, driven by improved PAN–OX spreads, Dahej at ~95% utilisation and positive OOSB EBITDA, though working-capital constraints limited raw-material procurement (ICRA, company presentation).
Balance sheet
Sources: S&P Global Market Intelligence (StockAnalysis, updated 4 Aug 2026); company net debt per FY26 Annual Report snapshot. The company's net-debt measure is ~INR 276 Cr lower than S&P's in FY26, most likely because the company nets long-term investments (e.g., its 14.38% stake in Ultramarine & Pigments, INR ~154 Cr in long-term investments) and excludes leases.
Commentary. The balance sheet has been transformed in four years: total debt rose 13x from INR 165 Cr to INR 2,175 Cr while CWIP rose from INR 64 Cr to INR 2,518 Cr — i.e., more than half of gross PP&E is non-earning US construction. Equity was rebuilt in FY26 only through ~INR 507 Cr of preferential equity (Aug and Dec 2025); without it, book equity would have fallen below INR 1,100 Cr. Working capital swung to INR -500 Cr as short-term debt and "other current liabilities" (INR 440 Cr, likely capex creditors and current maturities) ballooned; at 30 Jun 2026 consolidated current liabilities exceeded current assets by INR 742 Cr. Unencumbered consolidated cash was only ~INR 64 Cr at 31 Mar 2026 (ICRA).
Cash flow
Source: S&P Global Market Intelligence (StockAnalysis). FY2026 full-year cash-flow statement figures were not available in the sources reviewed; the trailing-twelve-month period to 30 Jun 2026 shows operating cash flow of INR -131 Cr, capex of INR 599 Cr, free cash flow of INR -730 Cr, D&A of INR 91 Cr and net borrowing of INR 284 Cr (S&P, Oct 2026). FY2026 equity inflow from preferential issues: ~INR 506.8 Cr. Note that cash interest paid (INR 128 Cr in FY25) far exceeds P&L finance cost (INR 44.5 Cr) because most interest on US project debt is capitalised during construction — a significant P&L flattering effect that will reverse once the plant is commissioned.
Commentary. Cumulative free cash flow over FY2023–FY2025 was INR -1,561 Cr, funded by ~INR 1,478 Cr of net new debt and cash drawdown; FY2026 added a further ~INR 700 Cr+ of negative FCF funded by equity and debt. Operating cash flow has been volatile and is now negative, reflecting stretched receivables (standalone debtor days 88 in FY26 vs. 40 in FY25) and losses.
Key ratios
Sources: ROE/ROCE — FY26 Annual Report snapshot; ROIC FY22–FY25 — S&P Global; FY26 ROIC derived (NOPAT on EBIT of INR -107 Cr at 25% tax over invested capital ≈INR 3,670 Cr); current ratio, D/E, asset turnover — S&P (FY26 derived from balance sheet); CCC and debtor days — Screener (standalone). Net debt/EBITDA FY26 is not meaningful because EBITDA is negative. ICRA metrics (consolidated): Total debt/OPBDIT 32.1x FY25 and -91.3x FY26; interest coverage 1.1x FY25, -0.3x FY26, 0.6x Q1 FY27; TOL/TNW 2.3x FY25, 2.0x FY26.
Commentary. Every return and coverage metric has collapsed from best-in-class (FY22 ROCE 28%) to value-destructive. The swing in the standalone cash conversion cycle from -21 to +61 days in a single year is particularly notable — TCL historically operated with negative working capital (supplier credit from Reliance on OX exceeded receivables and inventory), and the loss of that structural float (days payable fell from 103 to 63) suggests suppliers have tightened terms as credit quality weakened. Lenders' financial covenants were breached in FY26 and waived (ICRA).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Organic chemicals segment revenue (INR Cr, consolidated) | 2,083.1 | 2,049.5 | 1,735.5 |
Segment pre-tax result (INR Cr, consolidated PBT) | -35 | -41 | -202 |
Segment pre-tax margin (%) | -1.7 | -2.0 | -11.6 |
YoY revenue growth (%) | -2.3 | -1.6 | -15.3 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Group Entities
| Entity | Country | TCL ownership | Role |
|---|---|---|---|
Thirumalai Chemicals Ltd | India | Parent | Ranipet PAN, malic/fumaric acid, DEP; TCL-TE engineering division |
TCL Intermediates Pvt Ltd (TCLIPL) | India | 100% | Dahej PAN (phase I & II) and fumaric acid; designated material subsidiary |
Cheminvest Pte Ltd | Singapore | 100% | Holding company; majority shareholder of OOSB |
Optimistic Organic Sdn Bhd (OOSB) | Malaysia | 100% (step-down) | 50,000 TPA butane-based MAN plant at Kemaman; largely non-operational in FY26; divestment being explored |
TCL Global B.V. | Netherlands | 100% | Holding/trading (US structure) |
TCL Inc | USA | 100% | US holding entity |
TCL Specialties LLC | USA | 100% (step-down) | West Virginia MAN (40,500 TPA) and food-ingredients (30,000+ TPA) complex |
Lapiz Europe Ltd | UK | 100% | European trading/marketing |
Results by Segment
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Standalone revenue from operations (INR Cr) | 1,438 | 1,847 | 1,987 | 2,152 | 1,360 |
Consolidated revenue from operations (INR Cr) | 1,998.2 | 2,132.2 | 2,083.1 | 2,049.5 | 1,735.5 |
Standalone PAT (INR Cr) | 152 | 120 | 36 | 82 | -65 |
Consolidated PAT (INR Cr) | 281.2 | 89.8 | -38.8 | -46.1 | -167.9 |
Implied subsidiaries + eliminations PAT (INR Cr, derived) | 129.2 | -30.2 | -74.8 | -128.1 | -102.9 |
Standalone EBITDA (INR Cr, company) | 255 | 220 | 126 | 183 | 20 |
Consolidated EBITDA (INR Cr, company) | 452 | 216 | 70 | 69 | -16 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 1,998.2 | 2,132.2 | 2,083.1 | 2,049.5 | 1,735.5 |
Total income incl. other income (INR Cr) | 2,009.8 | 2,162.4 | 2,102.5 | 2,070.1 | 1,754.2 |
Gross profit (INR Cr) | 772.3 | 559.6 | 380.7 | 419.2 | 333.7 |
Operating income / EBIT (INR Cr) | 387.7 | 131.3 | -5.8 | -8.6 | -107.0 |
EBITDA (INR Cr, company-reported) | 452 | 216 | 70 | 69 | -16 |
Finance costs (INR Cr) | 16.9 | 26.2 | 35.9 | 44.5 | 80.6 |
Profit before tax (INR Cr) | 375 | 129 | -35 | -41 | -202 |
Net income (INR Cr) | 281.2 | 89.8 | -38.8 | -46.1 | -167.9 |
EPS basic and diluted (INR, derived) | 27.46 | 8.77 | -3.79 | -4.50 | -14.92 |
Dividend per share declared (INR) | 2.5 | 1.5 | 1.0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 38.65 | 26.25 | 18.28 | 20.45 | 19.23 |
Operating (EBIT) margin (%) | 19.4 | 6.2 | -0.3 | -0.4 | -6.2 |
EBITDA margin (%) | 22.6 | 10.1 | 3.4 | 3.4 | -0.9 |
Net margin (%) | 14.07 | 4.21 | -1.86 | -2.25 | -9.68 |
Revenue growth YoY (%) | 84.04 | 6.71 | -2.30 | -1.61 | -15.32 |
Income Statement
| Metric | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 450.05 | 445.37 | 415.85 | 424.25 | 546.67 |
Net profit (INR Cr) | -59.96 | -33.38 | -46.57 | -28.00 | -43.67 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 1,861.6 | 2,360.2 | 3,320.3 | 3,806.8 | 4,736.6 |
Cash and short-term investments (INR Cr) | 553.0 | 457.2 | 445.9 | 182.9 | 67.9 |
Short-term debt incl. current maturities (INR Cr) | 25.6 | 293.6 | 350.8 | 305.9 | 527.2 |
Long-term debt (INR Cr) | 135.4 | 147.6 | 812.5 | 1,400.7 | 1,565.8 |
Lease liabilities (INR Cr) | 4.1 | 72.9 | 88.4 | 79.1 | 81.7 |
Total debt incl. leases (INR Cr) | 165.1 | 514.0 | 1,251.7 | 1,785.6 | 2,174.7 |
Net debt, S&P basis (INR Cr) | -387.9 | 56.8 | 805.8 | 1,602.7 | 2,106.9 |
Net debt, company-reported (INR Cr) | -440 | -31 | 530 | 1,349 | 1,831 |
Shareholders' equity (INR Cr) | 1,085.0 | 1,191.9 | 1,146.2 | 1,155.7 | 1,563.6 |
Goodwill and intangibles (INR Cr) | 0.06 | 0.19 | 0.17 | 0.14 | 0.33 |
Net working capital (INR Cr) | 475.8 | 187.0 | 105.0 | 35.0 | -500.5 |
Net PP&E incl. CWIP (INR Cr) | 659.5 | 1,077.3 | 1,911.1 | 2,603.5 | 3,768.8 |
Capital work-in-progress (INR Cr) | 63.6 | 406.4 | 1,199.6 | 1,352.1 | 2,518.4 |
Inventory (INR Cr) | 242.0 | 319.2 | 250.8 | 247.3 | 184.7 |
Receivables (INR Cr) | 158.8 | 117.6 | 197.2 | 211.4 | 217.3 |
Book value per share (INR) | 105.97 | 116.41 | 111.95 | 112.87 | 129.66 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 220.8 | 402.3 | 54.1 | 237.1 | -65.9 |
Capital expenditure (INR Cr, outflow) | 61.0 | 73.6 | 362.8 | 810.7 | 612.9 |
Free cash flow (INR Cr) | 159.8 | 328.7 | -308.6 | -573.7 | -678.8 |
Dividends paid (INR Cr) | 0 | 22.3 | 25.6 | 15.4 | 10.2 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Net debt issued / (repaid) (INR Cr) | -15.9 | -29.0 | 267.6 | 697.4 | 512.7 |
Cash interest paid (INR Cr) | 22.3 | 18.6 | 19.6 | 79.1 | 127.8 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%, company-reported) | 26 | 8 | -3 | -4 | -11 |
ROCE (%, company-reported) | 28 | 19 | 0.4 | 0.5 | -10 |
ROA (%, PAT / year-end assets, derived) | 15.1 | 3.8 | -1.2 | -1.2 | -3.5 |
ROIC (%) | 21.67 | 5.55 | -0.18 | -0.29 | -2.2 |
Current ratio (x) | 1.86 | 1.22 | 1.10 | 1.04 | 0.61 |
Debt / equity (x) | 0.15 | 0.43 | 1.09 | 1.55 | 1.39 |
Net debt / EBITDA (x, company basis) | -0.97 | -0.14 | 7.57 | 19.55 | -114.4 |
Interest coverage, EBIT / finance cost (x) | 22.9 | 5.0 | -0.16 | -0.19 | -1.33 |
Asset turnover (x) | 1.25 | 1.01 | 0.73 | 0.57 | 0.41 |
Cash conversion cycle, standalone (days) | -44 | -28 | -32 | -21 | 61 |
Debtor days, standalone | 24 | 18 | 30 | 40 | 88 |
Revenue by Region and Revenue by Region (%)
| Metric | FY2026 |
|---|---|
Revenue from India (INR Cr) | 1,266 |
Export share of total revenue (%) | 10 |
Exports to Europe (% of exports) | 43 |
Exports to North America (% of exports) | 25 |
Exports to Asia (% of exports) | 19 |
Exports to Africa (% of exports) | 13 |
Share Price & Returns
| Horizon | Return | Source / date |
|---|---|---|
1 year | -49.6% | S&P Global, 7 Oct 2026 |
3 years | ~-27% (cumulative) | Anand Rathi, Aug 2026 |
5 years | ~+5% CAGR | Screener, mid-2026 |
10 years | ~+20% CAGR | Screener, mid-2026 |
52-week range | INR 143.5 – 328.8 | Fyers/Anand Rathi, Aug–Sep 2026 |
Beta (5Y) | 0.37 | S&P Global |
Relative performance | Underperformed commodity chemicals sector by ~49 pp over 1 year (as of Aug 2026) | MarketsMojo |
Share Price and Market Valuation
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Share price at FY end (INR) | 82.55 | 260.41 | 169.94 | 233.33 | 242.85 |
Market capitalisation (INR Cr) | 875.4 | 2,723.5 | 1,759.5 | 2,396.9 | 2,486.5 |
Enterprise value (INR Cr) | 816.5 | 2,394.6 | 1,231.8 | 2,762.4 | 3,452.3 |
EV/Sales (x) | 0.75 | 1.20 | 0.58 | 1.33 | 1.68 |
EV/EBITDA (x) | 3.70 | 5.43 | 6.75 | 54.45 | 70.75 |
P/B (x) | 1.09 | 2.51 | 1.48 | 2.09 | 2.15 |
Dividend yield (%) | 2.67 | 0.96 | 0.88 | 0.43 | 0 |
Capital Markets
| Metric | Thirumalai Chemicals | I G Petrochemicals |
|---|---|---|
Price | INR 147.70 (7 Oct 2026) | ~INR 555 (18 Sep 2026) |
Market cap | ~INR 1,781 Cr | ~INR 1,709 Cr |
Enterprise value | ~INR 3,888 Cr | — |
P/E (TTM) | n/m (loss) | Not meaningful/very high (near-zero TTM profit) |
EV/Sales (TTM) | 2.12x | — |
EV/EBITDA (TTM) | 83.8x | — |
P/B | 1.14x | 0.78x |
P/S | 0.97x | ~0.87x (derived from FY26 revenue) |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 2.5 | 1.5 | 1.0 | 0 | 0 |
Standalone payout ratio (%) | 17 | 13 | 28 | 0 | 0 |
Analyst Ratings & Targets
| Date | Long-term rating | Short-term rating | Driver |
|---|---|---|---|
4 Aug 2023 | A+ (Stable) | A1+ | Peak |
14 Feb 2024 | A+ (Negative) | A1+ | Weak FY24 margins, capex |
24 May 2024 | A+ (Negative) | A1 | — |
3 Dec 2024 | A+ (Negative) | A1 | Enhanced limits |
27 May 2025 | A (Negative) | A2+ | FY25 performance; US capex |
26 Aug 2025 | A- (Negative) | A2+ | Q1 FY26 weakness |
25 Nov 2025 | A- (Negative) | A2+ | Reaffirmed; NCDs rated |
12 Jan 2026 | BBB+ (Negative) | A2 | Weak PAN–OX spreads |
9 Jun 2026 | BBB+ (Negative) | A2 | Material-event update |
13 Aug 2026 | BBB (Negative) | A3+ | US cost to USD 340 m; delay; covenant breaches |
Capital Instruments
| Instrument | Amount (INR Cr) | Drawn / issued | Maturity | Coupon |
|---|---|---|---|---|
Term Loan I | 200 | 18 Dec 2023 | 3 Sep 2031 | — |
Term Loan II | 200 | 24 Oct 2024 | 30 Nov 2031 | — |
Term Loan III | 25 | 1 Nov 2024 | 31 Dec 2031 | — |
Term Loan IV | 20 | 15 Apr 2026 | 15 Apr 2029 | — |
NCD tranche 1 | 33 | 9 Jun 2025 | 4 Jun 2027 | 11.25% |
NCD tranche 2 | 33 | 9 Jun 2025 | 4 Jun 2028 | 11.75% |
NCD tranche 3 | 34 | 9 Jun 2025 | 4 Jun 2029 | 12.25% |
Working-capital limits (fund-based) | 334.5 | — | Revolving | — |
US subsidiary project debt | Not separately disclosed (guaranteed by TCL); new senior secured term loan up to USD 130 m in process | — | — | — |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance
No numeric guidance. Qualitative: improve EBITDA via volumes and realisations; control working capital; deleverage from operating cash flow; complete US commissioning by December 2026; raise up to INR 750 Cr and monetise non-core assets. Consensus growth expectations: not available (no sell-side coverage).
Bull case
-
Operating trough is behind: Q1 FY27 delivered INR 35.9 Cr EBITDA (6.6%) versus a loss a year earlier, the highest revenue in two years, Dahej at ~95% utilisation and positive OOSB EBITDA — with the anti-dumping duty secured to 2031, normalised Indian PAN spreads could restore INR 150–250 Cr of annual group EBITDA from existing Indian assets (FY23–FY24 levels were INR 70–216 Cr; FY22 INR 452 Cr).
-
US asset is close to cash generation: with MAN already producing in phases and full commissioning targeted for December 2026, roughly INR 2,500 Cr of CWIP converts to earning assets; ICRA expects higher-margin MAN and food acids to lift group margins and diversify geography.
-
Asset monetisation and equity support reduce tail risk: demonstrated access to ~INR 507 Cr equity in FY26 (including promoters), an INR 750 Cr enabling resolution, OOSB and windmill sales; at P/B of 1.14x the equity is priced near distressed levels.
Bear case
-
Serial cost and time overruns: budget has risen from USD 150 m (2022) to USD 340 m (2026) and timelines have slipped repeatedly; the funding gap is to be met with more debt, while capitalised interest will hit the P&L once the plant is commissioned — FY27–FY28 earnings may remain negative even with operating improvement.
-
Liquidity is the binding constraint: INR 64 Cr of unencumbered cash, INR 742 Cr negative working capital, covenant breaches, rising repayments (INR 388 Cr over FY27–FY28), short-term rating at A3+ and suppliers tightening credit (days payable 103 → 63) create refinancing and execution risk; working-capital shortages already capped Q1 FY27 volumes.
-
Dilution and structural competitiveness: any further INR 200–750 Cr of equity at ~INR 150/share could add 11–42% to the share count; core PAN remains a commodity where IGPL has larger scale and integration, and Chinese oversupply in MAN/food acids may limit US pricing.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Q2 FY27 results | ~3 Nov 2026 (estimated) | Sustainability of PAN–OX spread recovery; interest burden |
| Closing of US senior secured term loan (USD 130–180 m) | H2 2026 | Funds completion; removes cost-overrun funding gap |
| Execution of INR 200–750 Cr capital raise (preferential/QIP) | H2 FY27 | Liquidity; dilution |
| Full commissioning of West Virginia complex | Dec 2026 | Single largest value driver |
| Food-ingredient customer qualifications in US | 2,027 | Revenue ramp timing |
| OOSB divestment | FY27 | Removes loss-maker; cash inflow |
| ICRA rating action / outlook | Post-results | Funding cost and covenants |
| NCD tranche 1 maturity (INR 33 Cr) | 4 Jun 2027 | First market-debt test |
| GST SCN outcomes | FY27 | Contingent cash outflow |
| PAN–OX spread and OX pricing | Continuous | Core earnings driver |
Analyst verdict
Thirumalai Chemicals is a fundamentally sound commodity franchise trapped in a poorly timed, over-budget, debt-funded growth project. The Indian PAN business retains real advantages — a duopoly market position, assured Reliance feedstock, best-in-class energy integration and, as of August 2026, five more years of anti-dumping protection — and Q1 FY27 showed that, with even moderately better spreads, the standalone business returns to profit (INR 14 Cr PAT). The problem is the group balance sheet. In four years TCL has moved from INR 440 Cr of net cash to INR 1,831 Cr of company-reported net debt, its credit rating has fallen five notches to BBB (Negative)/A3+, covenants have been breached, and the West Virginia budget has more than doubled from its original plan to USD 340 million, with full commissioning now December 2026.
The investment case therefore hinges on a narrow sequence: close the US term loan, raise domestic capital, sell OOSB, commission West Virginia on the revised schedule, and qualify US food-ingredient customers quickly enough to generate cash before repayments intensify in FY2028. Each step is plausible — management has delivered INR 507 Cr of equity and phased US start-up — but the track record of slippage argues for skepticism, and the equity will likely absorb further dilution along the way.
At ~1.1x book and ~0.97x sales, the market already discounts significant distress, which creates asymmetric upside if the US plant ramps cleanly and Indian spreads hold. However, until liquidity is demonstrably repaired and the US asset is producing at scale, we view TCL as a high-risk, special-situation equity rather than a quality cyclical. Stance: speculative / avoid for risk-averse capital; monitor the Q2–Q3 FY27 prints, the US financing close and December 2026 commissioning as the triggers for re-rating. Credit investors should note that NCD coupons above 11% already price meaningful default-risk premia.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Education | Age |
|---|---|---|---|---|
R. Parthasarathy (DIN 00092172) | Chairman & Managing Director | Long-serving CMD (re-appointed multiple terms); President of Indian Chemical Council 2007–2011 (VP and President); has run manufacturing, technology development, marketing and start-ups in India, Europe and the US; Lifetime Achievement Award (FY26) | — | ~74 (GlobalData) |
Ramya Bharathram (DIN 06367352) | Managing Director & CFO; heads Strategy and Specialty Chemicals | On board since 3 Nov 2014; ~16+ years at TCL; previously at a trade-policy/indirect-tax law firm and Deloitte & Touche; re-appointed director (retires by rotation) at Aug 2026 AGM | Commerce graduate; Inter CA | 54 (DOB 24 Jul 1972) |
Sanjay Sinha | Chief Executive Officer | Listed as CEO in FY26 Annual Report and S&P profile; member of Risk Management Committee. Reported prior role as Executive Director, Emerging Business at Archean Group (GlobalData — not confirmed in company filings) | — | — |
Anand Kumar | President – Finance (Senior Management Personnel) | Appointed 14 Feb 2026 | — | — |
Aditya Sharma | Company Secretary & Compliance Officer | Signatory on 2026 filings | — | — |
Vinod Tiwari | CEO, TCL Specialties LLC (US subsidiary) | Joined Dec 2025 | — | — |
P. Mohana Chandran Nair | Non-Executive Director; MD of TCL Intermediates Pvt Ltd | ~11 years at TCL (formerly President-Manufacturing / Whole-time Director); 36+ years at Rashtriya Chemicals & Fertilizers, rising to Executive Director/Head of Operations | Chemical Engineer | 73 |
“—” = not publicly disclosed.
Board of Directors
| Director | Category | Committee roles | Prior / other roles | Age |
|---|---|---|---|---|
R. Parthasarathy | Executive Chairman & MD (Promoter) | CSR, Project Review | See above | ~74 |
Ramya Bharathram | Executive MD & CFO (Promoter group) | Risk Management, Fund Raising | Director, Jasmine Ltd; N.R. Swamy Investments; Indian Chemical Council | 54 |
P. Mohana Chandran Nair | Non-Executive | Stakeholders Relationship | Ex-RCF | 73 |
Rajeev M. Pandia | Independent | Chair: Nomination & Remuneration, Business Review, Risk Management; Audit; Fund Raising; Project Review | IIT Bombay / Stanford; former VC & MD Herdillia Chemicals (SI Group India); ex-President ICC; boards of Transpek Industry, Supreme Petrochem | 76 |
M. Somasundaram | Independent | Chair: Audit; Fund Raising; Project Review; Business Review | Ex-CFO of CAMS (led IPO); SRF, Hindustan Unilever; B.Com, ICWA, ACS | 63 |
Raj Kataria | Non-Executive (described as Independent in Annual Report bio; "Non-Executive" in AGM notice) | Chair: Stakeholders Relationship; Audit; NRC | Co-founder, Arpwood Capital; ex-MD DSP Merrill Lynch; director EIH Ltd | 70 |
Bhama Krishnamurthy | Independent | Chair: CSR; Audit; NRC; Risk Management | Ex-Country Head & CGM, SIDBI; boards incl. Cholamandalam Investment, Just Dial, Muthoot Microfin; TCL Global BV | 71 |
D. Sabitha | Independent | Audit; Stakeholders; CSR | Retired IAS (1988 batch), ex-Additional Chief Secretary, Tamil Nadu; director TCLIPL | 66 |
Meghav Mehta | Independent | CSR; Business Review; Risk Management | CEO Deepak Chem Tech; director Deepak Nitrite, Deepak Phenolics | 39 |
Arun Alagappan | Independent (resigned w.e.f. 31 Mar 2026) | — | Executive Vice Chairman, Coromandel International (Murugappa Group) | 49 |
Arun Ramanathan | Independent (retired 21 Jul 2025) | — | Ex-Union Finance Secretary | 77 |
R. Sampath | Non-Executive (resigned 14 Aug 2025; relative of CMD) | — | — | 80 |
Directors' Remuneration
| Name | Period | Remuneration | Source |
|---|---|---|---|
R. Parthasarathy (CMD) | H2 FY2023 related-party disclosure | INR 405.60 lakh | NSE RPT filing (May 2023) |
Ramya Bharathram (MD) | H2 FY2023 related-party disclosure | INR 245.76 lakh | NSE RPT filing (May 2023) |
FY2026 KMP remuneration | FY2026 | — | — |
Shareholding Trend
| Holder category | Jun 2025 (%) | Aug 2025 (%) | Dec 2025 (%) | Mar 2026 (%) | Jun 2026 (%) |
|---|---|---|---|---|---|
Promoter & promoter group | 41.87 | 36.13 | 37.13 | 37.13 | 37.13 |
Mutual funds | 0.73 | 7.91 | 8.46 | 8.91 | — |
Foreign institutional investors | 1.88 | 2.09 | 1.97 | 2.06 | — |
Other domestic institutions | 0.32 | 1.22 | 1.01 | 1.02 | — |
Retail and others | 55.19 | 52.65 | 51.42 | 50.86 | 51.33 |
Competitive Landscape
Key Competitors
| Competitor | Country | Product overlap | Relative positioning |
|---|---|---|---|
I G Petrochemicals Ltd (IGPL) | India | PAN, MAN, DEP, benzoic acid, plasticisers | India's largest PAN producer (~50% domestic share), sole domestic MAN producer; five PAN plants and four MAN plants at Taloja; adding 1,00,000 TPA plasticiser forward integration |
Chinese PAN producers (various) | China | PAN | Price setters for Asian PAN; subject to Indian ADD (USD 40.08/MT) |
Aekyung Chemical and other Korean PAN producers | South Korea | PAN | Subject to Indian ADD (USD 140.17/MT) |
Thai PAN producers | Thailand | PAN | DGTR found negative injury margin; no duty — potential import channel |
UPC Technology / Nan Ya Plastics | Taiwan | PAN, plasticisers | — |
Polynt Group | Italy/global | PAN, MAN, UPR | Integrated European/US anhydrides player |
Huntsman Corp | USA | MAN (US) | Leading US MAN producer — direct competitor to TCL Specialties |
Chinese MAN producers (various) | China | MAN | Oversupply source depressing Asian MAN prices; drove OOSB idling |
Bartek Ingredients | Canada | Malic acid, fumaric acid | Leading North American food-acids producer — direct competitor to US food-ingredients plant |
Fuso Chemical | Japan | Malic acid | Asian food-acids competitor |
Changmao Biochemical / Chinese malic acid producers | China | Malic and fumaric acid | Low-cost Asian food-acid supply |
Stepan / Koppers (historic PAN in US) | USA | PAN | US PAN producers (relevance to TCL limited given TCL's US focus is MAN) |
Peer Comparison FY2026
| Metric | Thirumalai Chemicals (FY2026, consolidated) | I G Petrochemicals (FY2026) |
|---|---|---|
Revenue | INR 1,735.5 Cr (revenue from ops) | INR 1,953.7 Cr (total revenue) |
Revenue growth YoY | -15.3% | -12.5% |
EBITDA margin | -0.9% | — |
Net profit | INR -167.9 Cr | ~INR 2.2 Cr (four quarters to Mar 2026, standalone) |
R&D intensity | 0.11% | — |
Market cap (Sep–Oct 2026) | ~INR 1,781 Cr | ~INR 1,709 Cr |
P/B | 1.14x | 0.78x |
Exports % of revenue | ~10% | ~11% |
Recent Developments
--



